1. 2004
2. Published

   Pharmacoeconomic models that incorporate non-compliance

   Hughes, D. & Hughes, D. A., 1 Jul 2004.

   Research output: Contribution to conference › Paper

3. Published

   Pharmacoeconomics appraisals by the all Wales medicines strategy group

   Hughes, D. & Hughes, D. A., 1 Jul 2004.

   Research output: Contribution to conference › Paper

4. Published

   Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

   Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Jun 2004, In: Pharmacogenetics. 14, 6, p. 335-342

   Research output: Contribution to journal › Article › peer-review

5. Published

   Patient compliance and persistence with prescribed medication: Measurement and health economic impact

   Hughes, D., Koncz, T., Hughes, D. A., Cleemput, I. & Annemans, L., 1 May 2004.

   Research output: Contribution to conference › Paper

6. Published

   Pharmacoeconomics in Wales: functions of the all Wales medicines strategy group

   Hughes, D. & Hughes, D. A., 1 Apr 2004.

   Research output: Contribution to conference › Paper

7. Published

   Pharmacoeconomics of pharmacogenetic testing: azathioprine

   Hughes, D., McAllister, R. & Hughes, D. A., 1 Apr 2004.

   Research output: Contribution to conference › Paper

8. Published

   Approaches to pharmacoeconomic analysis

   Hughes, D., Hughes, D. A., Walley, T. (ed.), Haycox, A. (ed.), Boland, A. (ed.) & Breckenridge, A. (ed.), 1 Jan 2004, Pharmacoeconomics. 2004 ed. Adis International, p. 101-126

   Research output: Chapter in Book/Report/Conference proceeding › Chapter

9. Published

   Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

   Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Jan 2004, In: Drug Safety. 27, 8, p. 535-554

   Research output: Contribution to journal › Article › peer-review

10. Published

    Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Jan 2004, In: Pharmacoeconomics. 22, 16, p. 1047-1059

    Research output: Contribution to journal › Article › peer-review

11. Published

    Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Belgium.

    Hughes, D. & Hughes, D. A., 1 Jan 2004, 2004 ed. Unknown.

    Research output: Book/Report › Commissioned report

12. Published

    Modelling in health economics

    Hughes, D., Hughes, D. A., Walley, T. (ed.), Haycox, A. (ed.), Boland, A. (ed.) & Breckenridge, A. (ed.), 1 Jan 2004, Pharmacoeconomics. 2004 ed. Adis International, p. 141-154

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

13. Published

    The future challenges

    Hughes, D., Hughes, D. A., Walley, T. (ed.), Haycox, A. (ed.), Boland, A. (ed.) & Breckenridge, A. (ed.), 1 Jan 2004, Pharmacoeconomics. 2004 ed. Adis International, p. 167-174

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

14. 2003
15. Published

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Dec 2003.

    Research output: Contribution to conference › Paper

16. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003.

    Research output: Contribution to conference › Paper

17. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003, In: Value in Health. 6, 6, p. 749

    Research output: Contribution to journal › Article › peer-review

18. Published

    Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Nov 2003, In: Value in Health. 6, 6, p. 613

    Research output: Contribution to journal › Article › peer-review

19. Published

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

20. Published

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

21. Published

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

22. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Sept 2003.

    Research output: Contribution to conference › Paper

23. Published

    Modelling changes in first line antimalarial therapy

    Hughes, D. & Hughes, D. A., 1 Sept 2003.

    Research output: Contribution to conference › Paper

24. Published

    Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modelling.

    Hughes, D., Hughes, D. A. & Walley, T., 1 Jul 2003, In: Clinical Pharmacology and Therapeutics. 74, 1, p. 1-8

    Research output: Contribution to journal › Article › peer-review

25. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Jun 2003.

    Research output: Contribution to conference › Paper

26. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 May 2003.

    Research output: Contribution to conference › Paper

27. 2002
28. Published

    Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Nov 2002.

    Research output: Contribution to conference › Paper